Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment

Korábbi kezelés

• Previous history of CAD event (angina, unstable angina, acute myocardial infarction) or ischemic stroke

Más betegség

• With other malignant disease
• Allergy to statin

Laborértékek

• Advanced CKD (eGFR\<30) or ESRD

Életkor

• Severe comorbidity with life expectancy \< 2 years

Egyéb

• Undetermined nature of hepatic tumor
• HCC with extrahepatic metastasis or major vascular invasion
• Child Pugh score \>7
• Hyperlipidemia or other indication for statin (according to Taiwan NHI guideline)

• Individuals with HCC BCLC stage 0 or A who received curative radiofrequency ablation or hepatic resection could be eligible.
• Individuals who had single HCC (size \> 5.0 cm) received hepatic resection would be eligible
• Individuals with prior history of HCC who had ever received curative ablation or hepatic resection without any recurrence for more than 2 years could be eligible if they had a new episode of recurrent HCC which could meet either of the former two criteria.
• After 12+/-1 weeks of curative treatment, eligible patients who have no evidence of local residual or recurrent tumors according to the dynamic CT or MRI could be enrolled
• The diagnosis of fresh HCC should be compatible with either pathological report or meet the criteria of AASLD guidelines